Mounjaro acts on two naturally occurring incretin hormone pathways, GIP and GLP-1, helping regulate appetite, fullness, digestion and blood sugar
Once reconstituted with bacteriostatic water, peptides typically remain stable for several weeks under refrigeration
No FDA-approved brand-name options
The medication binds with GLP-1 receptors in your brain (hypothalamus), particularly in the areas responsible for controlling hunger and satiety
Research shows that approximately 5060% of weight lost during GLP-1 therapy can return within one to two years after stopping, particularly if lifestyle habits remain unchanged
Understanding potential overlapping side effects, monitoring requirements, and UK regulatory guidance is essential